Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Other Operating Expenses (2020 - 2025)

Vivos Therapeutics' Other Operating Expenses history spans 6 years, with the latest figure at -$5.8 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at -$5.8 million for Q4 2025, down 71.11% from a year ago — trailing twelve months through Dec 2025 was -$10.8 million (down 42.86% YoY), and the annual figure for FY2025 was -$21.2 million, down 77.65%.
  • Other Operating Expenses for Q4 2025 was -$5.8 million at Vivos Therapeutics, down from -$5.5 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $2.3 million in Q4 2021 to a low of -$5.8 million in Q4 2025.
  • The 5-year median for Other Operating Expenses is $664500.0 (2023), against an average of -$220229.8.
  • The sharpest move saw Other Operating Expenses soared 361.36% in 2021, then plummeted 708.65% in 2024.
  • Year by year, Other Operating Expenses stood at $2.3 million in 2021, then plummeted by 46.69% to $1.2 million in 2022, then plummeted by 54.66% to $555000.0 in 2023, then tumbled by 708.65% to -$3.4 million in 2024, then tumbled by 71.11% to -$5.8 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at -$5.8 million, -$5.5 million, and $100000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.